Skip to main content

Market Overview

Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M

Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) will acquire Semma Therapeutics, a privately held biotechnology company that uses of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash.

Semma has a differentiated approach to treat type 1 diabetes, which is a disease affecting over one million people in the U.S. alone.

“Semma has made two major scientific advances: the ability to produce large quantities of functional human pancreatic beta cells that restore insulin secretion and ameliorate hypoglycemia in animal models and a novel device that encapsulates and protects these cells from the immune system, enabling durable implantation without the need for ongoing immunosuppressive therapy,” Vertex said in a statement.

Vertex Pharmaceuticals shares were trading up 0.82% at $181.50 in Tuesday’s pre-market session. The stock has a 52-week high of $195.81 and a 52-week low of $151.80.

Related Links:

Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary

Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: Semma TherapeuticsBiotech M&A News General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at